AU2002247007B2 - Use of compositions containing PDGF-BB for promoting angiogenesis - Google Patents

Use of compositions containing PDGF-BB for promoting angiogenesis Download PDF

Info

Publication number
AU2002247007B2
AU2002247007B2 AU2002247007A AU2002247007A AU2002247007B2 AU 2002247007 B2 AU2002247007 B2 AU 2002247007B2 AU 2002247007 A AU2002247007 A AU 2002247007A AU 2002247007 A AU2002247007 A AU 2002247007A AU 2002247007 B2 AU2002247007 B2 AU 2002247007B2
Authority
AU
Australia
Prior art keywords
pdgf
angiogenesis
vegf
tissue
fgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002247007A
Other languages
English (en)
Other versions
AU2002247007A1 (en
Inventor
Renhai Cao
Yihai Cao
Philippe Leboulch
Robert Pawliuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bluebird Bio Inc
Original Assignee
Genetix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetix Pharmaceuticals Inc filed Critical Genetix Pharmaceuticals Inc
Publication of AU2002247007A1 publication Critical patent/AU2002247007A1/en
Application granted granted Critical
Publication of AU2002247007B2 publication Critical patent/AU2002247007B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AU2002247007A 2001-01-26 2002-01-18 Use of compositions containing PDGF-BB for promoting angiogenesis Ceased AU2002247007B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26445701P 2001-01-26 2001-01-26
US60/264,457 2001-01-26
PCT/US2002/001666 WO2002058718A2 (fr) 2001-01-26 2002-01-18 Methodes et compositions permettant de stimuler l'angiogenese

Publications (2)

Publication Number Publication Date
AU2002247007A1 AU2002247007A1 (en) 2003-02-06
AU2002247007B2 true AU2002247007B2 (en) 2006-12-07

Family

ID=23006154

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002247007A Ceased AU2002247007B2 (en) 2001-01-26 2002-01-18 Use of compositions containing PDGF-BB for promoting angiogenesis

Country Status (5)

Country Link
EP (1) EP1355659A2 (fr)
JP (1) JP4434584B2 (fr)
AU (1) AU2002247007B2 (fr)
CA (1) CA2436076A1 (fr)
WO (1) WO2002058718A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
JP2005168654A (ja) * 2003-12-09 2005-06-30 Kissei Pharmaceut Co Ltd 増殖因子結合低分子ヘパリン修飾体
FR2891149B1 (fr) * 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
JP5025646B2 (ja) * 2005-11-08 2012-09-12 公益財団法人先端医療振興財団 虚血性心疾患の治療方法
FR2914191A1 (fr) * 2007-03-29 2008-10-03 Proteins & Peptides Man Composition angiogenique.
BRPI0913684A2 (pt) * 2008-09-26 2015-10-20 Adocia complexo composto por um polissacarídeo substituído por um triptofano ou um derivado de triptofano a partir de uma proteína ligadora à heparina, composição farmacêutica e seus usos
WO2010078624A1 (fr) * 2009-01-07 2010-07-15 Vegenics Limited Matériaux et méthodes pour le traitement de l’hypertension
GB201504665D0 (en) * 2015-03-19 2015-05-06 Cell Therapy Ltd Composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000060A1 (fr) * 1988-06-30 1990-01-11 Collagen Corporation Matrices collagenes de cicatrisation de blessures et leur procede de production
WO1991016009A1 (fr) * 1990-04-17 1991-10-31 Curative Technologies, Inc. Procede utilise pour recouvrir des surfaces de protheses avec des cellules de mammiferes
US5128321A (en) * 1986-08-13 1992-07-07 Zymogenetics, Inc. PDGF analogs and methods of use
WO1994025056A2 (fr) * 1993-04-29 1994-11-10 Washington University Utilisation du facteur de croissance derive des plaquettes pour l'amelioration de la circulation collaterale
WO1997012601A2 (fr) * 1995-10-06 1997-04-10 Ethicon, Inc. Formulations de gel contenant des facteurs de croissance
WO2000041732A1 (fr) * 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Compositions hydrogel pour l'administration controlee de vecteurs viraux, et leurs procedes d'utilisation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128321A (en) * 1986-08-13 1992-07-07 Zymogenetics, Inc. PDGF analogs and methods of use
WO1990000060A1 (fr) * 1988-06-30 1990-01-11 Collagen Corporation Matrices collagenes de cicatrisation de blessures et leur procede de production
WO1991016009A1 (fr) * 1990-04-17 1991-10-31 Curative Technologies, Inc. Procede utilise pour recouvrir des surfaces de protheses avec des cellules de mammiferes
WO1994025056A2 (fr) * 1993-04-29 1994-11-10 Washington University Utilisation du facteur de croissance derive des plaquettes pour l'amelioration de la circulation collaterale
WO1997012601A2 (fr) * 1995-10-06 1997-04-10 Ethicon, Inc. Formulations de gel contenant des facteurs de croissance
WO2000041732A1 (fr) * 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Compositions hydrogel pour l'administration controlee de vecteurs viraux, et leurs procedes d'utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Edelman ER et al, Biomaterials, September 1991, vol 12, no 7, pages 619-626 *
Kawaki K et al, Biomaterials, March 2000, vol 21, no 5, pages 489-499 *
Liechty KW et al, J. Invest Dermatol, September 2999, vol 113, no 3, pages 375-383 *
Steed DL et al, J Vascular Surgery, January 1995, vol 1, no 21, pages 71-81 *

Also Published As

Publication number Publication date
EP1355659A2 (fr) 2003-10-29
JP2005506279A (ja) 2005-03-03
WO2002058718A3 (fr) 2003-04-17
WO2002058718A2 (fr) 2002-08-01
JP4434584B2 (ja) 2010-03-17
CA2436076A1 (fr) 2002-08-01

Similar Documents

Publication Publication Date Title
AU2001268149B2 (en) Methods and compounds for controlled release of recombinant parvovirus vectors
US20030139333A1 (en) Methods and compositions for promoting angiogenesis
US20020172663A1 (en) Localized myocardial injection method for treating ischemic myocardium
CN1198675A (zh) 含有hgf基因的药物
AU2002247007B2 (en) Use of compositions containing PDGF-BB for promoting angiogenesis
US20080102059A1 (en) Treatment for arthritis
AU772857B2 (en) Method of inducing angiogenesis
AU2002247007A1 (en) Use of compositions containing PDGF-BB for promoting angiogenesis
CN103638002A (zh) 包囊的肝细胞组合物
JP2007501282A (ja) 哺乳類の四肢の細胞へのポリヌクレオチドの静脈内送達
WO1989007944A1 (fr) Procede et dispositif de neovascularisation a localisation controlee
Goodrich Gene therapy and tissue engineering
CN1630538A (zh) 用vegf－b刺激血管生成
ES2434257T3 (es) Coágulos de células hematopoyéticas no poliméricos para suministro de agentes activos
KR20190050277A (ko) 허혈성 심혈관 질환의 치료용 또는 예방용 약학 조성물
JP2014218509A (ja) 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入
US20020013261A1 (en) Methods and compositions for promoting angiogenesis using polyethylene glycol (PEG) polymers
US20070123486A1 (en) Composition for coordinated VEGF and PDGF expression, and methods of use
Vranckx et al. 15 Gene Transfer of Growth Factors for Wound Repair
Wang et al. In vitro circadian ANP secretion by gene transferring cells encapsulated in polycaprolactone tubes: gene chronotherapy
Davidson 13 Gene Therapy of Wounds
EP1556494A2 (fr) Boite d'expression, vecteur de plasmide a deux cistrons, produit pharmaceutique et leur utilisation en therapie genique angiogenique
Wnek et al. Gene-Activated Matrix/Neil Davies
e Silva Engineering vascular networks
Aslan et al. 184. Nonvirally Electrotransfected Human Mesenchymal Stem Cells: A Novel Platform for Bone Gene Therapy Based on Autocrine and Paracrine Mechanisms

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired